Clinical Trial Update: A Study on the Efficacy and Safety of IPyC for HER2+ MBC

View source ↗

Summary

This is a completed clinical trial evaluating the efficacy and safety of IPyC for HER2-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IPyC

Snippet

Sponsor: Fujian Medical University | Conditions: Breast Cancer | Status: COMPLETED